BCL2 and cancer: Similarly, the drastic change in the transcriptional profile of senescent cells has also been shown to limit the success of current anti-cancer therapy—the upregulation of pro-survival, anti-apoptotic signals such as BCL-2, as a result of transcriptional changes, is thought to desensitise senescent cells to apoptosis, which diminishes the effectiveness of anti-cancer therapies that employ apoptosis-inducing strategies [127,128].